Provenance and clinical benefit of medicines introduced to the French market, 2008 to 2018

Osipenko, Leeza, Potey, Philippe, Perez, Bernardo, Kupryjanczuk, Alexandra, Angelov, Filip, Schuster, Alexandra and Mossialos, Elias (2023) Provenance and clinical benefit of medicines introduced to the French market, 2008 to 2018. JAMA Internal Medicine. ISSN 2168-6106

Text (Provenance and Clinical Benefit of Medicines Introduced to the French Market, 2008 to 2018) - Published Version Available under License Creative Commons Attribution. Download (422kB)

• Scopus publication
• Author
• Author

Abstract

IMPORTANCE Both the commercial sector and academia play a vital role in medicine development. Ongoing debates exist on their contribution and the value of medicinal products entering the market. OBJECTIVE To identify the provenance and clinical benefit of medicines that entered the French market between 2008 and 2018. DESIGN AND SETTING In this cross-sectional study, the provenance of each medicine in the French market was established via a review of multiple sources documenting at least 2 matching findings per product. The clinical benefit was assigned using the matched scale developed from the Prescrire and Haute Autorité de Santé (HAS) gradings. The χ2 test was used to analyze the proportions and frequencies of medicines graded by Prescrire and HAS by origin, therapeutic category, and clinical benefit. MAIN OUTCOMES AND MEASURES The origins and therapeutic categories of medicines. Clinical benefit based on Prescrire and HAS grading. Concordance of Prescrire and HAS grading. RESULTS Of the 632 medicines that entered the French market between 2008 and 2018, 464 originated (73%) in the commercial sector, and 168 originated (27%) in the academic setting or in collaboration with commercial enterprises. Prescrire graded psychotropic agents (13/14 [93%]), whereas HAS graded respiratory agents (24/25 [96%]) as the highest percentage of medicines that provided no added benefit. Prescrire graded 360 medicines (77.6%) that originated in the industry and 108 medicines (64.3%) that originated in the academic setting (P = .001) to have no added clinical benefit. HAS assigned such grading to 331 ([71.3%] industry) vs 104 ([61.9%] academia) (P = .02). Based on the Prescrire grading, academia invented more medicines delivering some added benefit 57 (33.9%) vs 98 (21.1%) invented by industry (P = .001). HAS grading on some added benefit 51 ([30.4%] academia) vs 121 ([26.1%] industry) did not reach statistical significance (P = .29). However, HAS grading on substantial added clinical benefit reached statistical significance in favor of academia (13 [7.7%] vs 12 [2.6%] in the industry; P = .003), whereas Prescrire grading did not (1.8% academia vs 1.3% industry; P = .64). CONCLUSIONS AND RELEVANCE More than 70% of medicines that entered the French market during the 10-year period originated in the commercial sector. Although most medicines were not graded as providing clinical benefit, medicines originating in the academic setting were more likely to be graded as conferring clinical benefit than those originating in the commercial setting.

Item Type:	Article
Additional Information:	© 2023 The Author(s)
Divisions:	Health Policy LSE
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited:	12 Jan 2024 12:09
Last Modified:	15 Jan 2024 11:09
URI:	http://eprints.lse.ac.uk/id/eprint/121360

Actions (login required)

View Item